249 related articles for article (PubMed ID: 29803930)
1. Candidate biomarkers for Parkinson's disease.
Khodadadian A; Hemmati-Dinarvand M; Kalantary-Charvadeh A; Ghobadi A; Mazaheri M
Biomed Pharmacother; 2018 Aug; 104():699-704. PubMed ID: 29803930
[TBL] [Abstract][Full Text] [Related]
2. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease.
Arshad AR; Sulaiman SA; Saperi AA; Jamal R; Mohamed Ibrahim N; Abdul Murad NA
Front Mol Neurosci; 2017; 10():352. PubMed ID: 29163029
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease.
Fricova D; Harsanyiova J; Kralova Trancikova A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212934
[TBL] [Abstract][Full Text] [Related]
5. Different iron deposition patterns in early- and middle-late-onset Parkinson's disease.
Xuan M; Guan X; Gu Q; Shen Z; Yu X; Qiu T; Luo X; Song R; Jiaerken Y; Xu X; Huang P; Luo W; Zhang M
Parkinsonism Relat Disord; 2017 Nov; 44():23-27. PubMed ID: 28838722
[TBL] [Abstract][Full Text] [Related]
6. Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease--a study from Southwest China.
Guo X; Song W; Chen K; Chen X; Zheng Z; Cao B; Huang R; Zhao B; Wu Y; Shang HF
Parkinsonism Relat Disord; 2013 Nov; 19(11):961-5. PubMed ID: 23849500
[TBL] [Abstract][Full Text] [Related]
7. Updating Our Definitions of Parkinson's Disease for a Molecular Age.
Chen-Plotkin AS; Zetterberg H
J Parkinsons Dis; 2018; 8(s1):S53-S57. PubMed ID: 30584165
[TBL] [Abstract][Full Text] [Related]
8. Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.
Giri B; Seamon M; Banerjee A; Chauhan S; Purohit S; Morgan J; Baban B; Wakade C
Metab Brain Dis; 2022 Aug; 37(6):1687-1696. PubMed ID: 33881722
[TBL] [Abstract][Full Text] [Related]
9. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Parkinson's Disease: How Good Are They?
Li T; Le W
Neurosci Bull; 2020 Feb; 36(2):183-194. PubMed ID: 31646434
[TBL] [Abstract][Full Text] [Related]
11. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
[TBL] [Abstract][Full Text] [Related]
12. An update on new-age potential biomarkers for Parkinson's disease.
Soni R; Mathur K; Shah J
Ageing Res Rev; 2024 Feb; 94():102208. PubMed ID: 38296162
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
14. Tears - more to them than meets the eye: why tears are a good source of biomarkers in Parkinson's disease.
Edman MC; Janga SR; Kakan SS; Okamoto CT; Freire D; Feigenbaum D; Lew M; Hamm-Alvarez SF
Biomark Med; 2020 Feb; 14(2):151-163. PubMed ID: 32064896
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for the diagnosis and management of Parkinson's disease.
Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease biomarkers based on α-synuclein.
Fayyad M; Salim S; Majbour N; Erskine D; Stoops E; Mollenhauer B; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):626-636. PubMed ID: 31265130
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S; Raymick J; Imam S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
[TBL] [Abstract][Full Text] [Related]
18. Salivary Biomarkers for Parkinson's Disease: A Systematic Review with Meta-Analysis.
Nijakowski K; Owecki W; Jankowski J; Surdacka A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391952
[TBL] [Abstract][Full Text] [Related]
19.
Sasannezhad P; Juibary AG; Sadri K; Sadeghi R; Sabour M; Kakhki VRD; Alizadeh H
Asia Ocean J Nucl Med Biol; 2017; 5(2):114-119. PubMed ID: 28660222
[TBL] [Abstract][Full Text] [Related]
20. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
